• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page
Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

Mar 6, 2022 | Triple Negative Breast Cancer

A deep learning-based iterative digital pathology annotation tool

A deep learning-based iterative digital pathology annotation tool

Aug 24, 2021 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

May 20, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

Overcoming hypoxia-induced functional suppression of NK cells

Overcoming hypoxia-induced functional suppression of NK cells

Apr 8, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly-Informed Integrated Immunotherapy Combining Innate High-Affinity Natural Killer (haNK) Cell Therapy with Adenoviral & Yeast-based Vaccines and Immune Checkpoint Inhibitor to Induce T-Cell Responses in Subjects with TNBC Who Have Progressed on or after Standard-of-Care Therapy

Dec 11, 2019 | Triple Negative Breast Cancer

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater Triple-Negative Breast Cancer (TNBC)

May 26, 2019 | Triple Negative Breast Cancer

Recent Posts

  • LUGPA 2025 Annual Meeting
  • ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
  • ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
  • UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
  • LUGPA Regional Meeting
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap